Physician profile
Scott Hallgren
NPI 1205929841
$5,704.94
in general payments reported to CMS, 2019-2025
31 companies · $861 in 2025
The $861 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $277 · 2021: $1,005 · 2022: $1,370 · 2023: $1,011 · 2024: $556 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,428.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,317.41 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $566.72 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $385.50 | 2019-2025 | Eohilia, Entyvio |
| Gilead Sciences, INC. | $300.40 | 2019-2025 | |
| Janssen Biotech, INC. | $262.90 | 2019-2025 | Stelara, Tremfya, Simponi |
| Pfizer INC. | $214.28 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $189.48 | 2019-2024 | Dificid |
| Celgene Corporation | $155.59 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $127.44 | 2019-2024 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $119.73 | 2022-2025 | Dupixent |
| Olympus America INC. | $111.50 | 2019-2021 | |
| Redhill Biopharma INC. | $103.48 | 2021-2023 | Movantik, Talicia, Aemcolo |
| Genzyme Corporation | $100.91 | 2022-2025 | |
| Ardelyx, INC. | $89.81 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $87.49 | 2024-2025 | Omvoh |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $84.82 | 2019-2024 | Sucraid |
| Phathom Pharmaceuticals, INC. | $69.34 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $51.30 | 2019-2025 | |
| Capsovision, INC. | $50.59 | 2025 | Capsocam Plus |
| Medtronic, INC. | $48.52 | 2023 | Intellis Adaptivestim |
| Echosens North America, INC. | $40.30 | 2024 | Fibroscan |
| Nestle Healthcare Nutrition INC. | $40.17 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $33.15 | 2023 | Idacio |
| Alfasigma USA, INC. | $31.86 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.33 | 2023 | Cyltezo |
| Conmed Corporation | $24.98 | 2023 | Conmed Generators |
| Ironwood Pharmaceuticals, INC | $18.90 | 2021 | |
| Mirum Pharmaceuticals, INC. | $14.83 | 2025 | Livmarli |
| Amgen INC. | $14.46 | 2023 | Avsola, Amjevita |
| Allergan, INC. | $11.56 | 2019 | |
| Organon LLC | $8.19 | 2023 | Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hallgren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.